Tag: executive

GREENVILLE, South Carolina, June 09, 2026 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) announces that its Board of Directors has appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange (the “TSXV” or the “Exchange”), including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures.

Incline Village, NV, June 09, 2026 (GLOBE NEWSWIRE) -- RMG ML Sports Holdings (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chief Executive Officer, James Carpenter, and President and Chief Financial Officer, Douglas Horlick, today announced the pricing of its initial public offering of 20,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one right to receive one-eighth (1/8) of one Class A ordinary share upon the consummation of the Company’s initial business combination. The units are expected to trade on the Global Market tier of the Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “SHOTU” beginning June 10, 2026. Once the securities comprising the units begin separate trading, the ordinary shares and the rights are expected to be traded on Nasdaq under the symbols “SHOT” and “SHOTR,” respectively.

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today announced the results of its annual meeting of shareholders held on June 9, 2026 (the “Meeting”). Common shareholders at the Meeting affirmatively approved the following resolutions:

WINNIPEG, Manitoba, June 09, 2026 (GLOBE NEWSWIRE) -- (TSX: NWC): The North West Company Inc. (the "Company" or "North West") today reported its unaudited financial results for the first quarter ended April 30, 2026. It also announced that the Board of Directors has declared a quarterly dividend of $0.41 to shareholders of record on June 30, 2026, to be paid on July 15, 2026.

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).